Investigation Launched Against Sarepta Therapeutics by Pomerantz LLP
New York, NY – May 10, 2025 – Pomerantz LLP, a leading national securities law firm, is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). The investigation concerns potential violations of the Securities Exchange Act of 1934 by Sarepta and certain of its officers and directors.
Background
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare and life-threatening diseases. The Company’s primary focus is on its exon skipping technology, which is designed to correct the genetic defects that cause certain rare diseases.
The Allegations
The investigation concerns whether Sarepta and certain of its executives and directors violated securities laws by making false and misleading statements regarding the safety and efficacy of Eticoximab, a monoclonal antibody used in the treatment of malignant atrial arrhythmias. The allegations include that the Company downplayed the risks associated with Eticoximab and failed to disclose material information regarding the drug’s safety profile.
Implications for Individual Investors
If you are a shareholder of Sarepta Therapeutics and believe that you have suffered a loss as a result of the alleged securities law violations, you may be entitled to recover your losses. Under the Securities Exchange Act of 1934, investors may be entitled to recover damages if they suffered a loss as a result of the Company’s violations. To discuss your legal rights, contact Danielle Peyton at [email protected] or 646-581-9980, ext. 167.
Global Implications
The investigation against Sarepta Therapeutics has broader implications for the biopharmaceutical industry as a whole. The allegations raise concerns about the regulatory oversight of drug development and the potential for pharmaceutical companies to downplay risks or misrepresent data to secure regulatory approval and maximize profits. This could potentially lead to increased scrutiny of the industry and calls for greater transparency and accountability.
Conclusion
The investigation launched by Pomerantz LLP against Sarepta Therapeutics highlights the importance of transparency and accountability in the biopharmaceutical industry. As investors, it is crucial that we are informed about the risks and benefits of the drugs we invest in and that companies are held accountable for any misrepresentations or violations of securities laws. If you are a shareholder of Sarepta Therapeutics and believe that you have been affected by the alleged securities law violations, it is important that you seek legal advice to protect your rights.
- Sarepta Therapeutics is the subject of an investigation by Pomerantz LLP for potential securities law violations related to Eticoximab.
- The allegations include downplaying risks and failing to disclose material information regarding the drug’s safety profile.
- Individual investors who believe they have suffered losses may be entitled to recover damages.
- The investigation has broader implications for the biopharmaceutical industry, raising concerns about regulatory oversight and transparency.
